1.74
+0.03(+1.75%)
Currency In USD
| Previous Close | 1.71 |
| Open | 1.67 |
| Day High | 1.74 |
| Day Low | 1.67 |
| 52-Week High | 9.5 |
| 52-Week Low | 1.28 |
| Volume | 2,265.01 |
| Average Volume | 99,452 |
| Market Cap | 3.33M |
| PE | 1.49 |
| EPS | 1.17 |
| Moving Average 50 Days | 1.88 |
| Moving Average 200 Days | 4.03 |
| Change | 0.03 |
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
GlobeNewswire Inc.
Feb 02, 2026 1:30 PM GMT
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a deve
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
GlobeNewswire Inc.
Jan 12, 2026 1:30 PM GMT
Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”)
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
GlobeNewswire Inc.
Dec 22, 2025 3:15 PM GMT
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below rates typically observed with other FDA approved c